These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838 [TBL] [Abstract][Full Text] [Related]
5. Folate and antifolate pharmacology. Kamen B Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-30-S18-39. PubMed ID: 9420019 [TBL] [Abstract][Full Text] [Related]
6. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions. Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030 [TBL] [Abstract][Full Text] [Related]
7. Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. Experimental and network thermodynamic analyses of the role of dihydrofolate polyglutamylates in antifolate action in cells. Seither RL; Trent DF; Mikulecky DC; Rape TJ; Goldman ID J Biol Chem; 1989 Oct; 264(29):17016-23. PubMed ID: 2529254 [TBL] [Abstract][Full Text] [Related]
8. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554 [TBL] [Abstract][Full Text] [Related]
9. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells. Rhee MS; Galivan J; Wright JE; Rosowsky A Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264 [TBL] [Abstract][Full Text] [Related]
10. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines. Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632 [TBL] [Abstract][Full Text] [Related]
11. Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL Semin Oncol; 1999 Apr; 26(2 Suppl 6):48-54. PubMed ID: 10598555 [TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate. Li WW; Tong WP; Bertino JR Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025 [TBL] [Abstract][Full Text] [Related]
13. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells. Temmink OH; Hoogeland MF; Fukushima M; Peters GJ Cancer Chemother Pharmacol; 2006 Jan; 57(2):171-9. PubMed ID: 16010590 [TBL] [Abstract][Full Text] [Related]
14. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783 [TBL] [Abstract][Full Text] [Related]
15. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein. Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196 [TBL] [Abstract][Full Text] [Related]
16. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization. McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096 [TBL] [Abstract][Full Text] [Related]
17. Elevation of dihydrofolate reductase, thymidylate synthetase, and thymidine kinase in cultured mammalian cells after exposure to folate antagonists. Chello PL; McQueen CA; DeAngelis LM; Bertino JR Cancer Res; 1976 Jul; 36(7 PT 1):2442-9. PubMed ID: 1277151 [TBL] [Abstract][Full Text] [Related]
18. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate. Galivan J; Nimec Z; Rhee M; Boschelli D; Oronsky AL; Kerwar SS Cancer Res; 1988 May; 48(9):2421-5. PubMed ID: 2965613 [TBL] [Abstract][Full Text] [Related]
19. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Zhao R; Zhang S; Hanscom M; Chattopadhyay S; Goldman ID Clin Cancer Res; 2005 Feb; 11(3):1294-301. PubMed ID: 15709201 [TBL] [Abstract][Full Text] [Related]
20. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]